https://journalaorj.com/index.php/AORJ/issue/feed Asian Oncology Research Journal 2023-03-14T13:00:00+00:00 Asian Oncology Research Journal contact@journalaorj.com Open Journal Systems <p style="text-align: justify;"><strong>Asian Oncology Research Journal</strong>&nbsp;aims to publish&nbsp;high-quality&nbsp;papers (<a href="/index.php/AORJ/general-guideline-for-authors">Click here for Types of paper</a>) in all areas of&nbsp;‘Cancer, Tumor&nbsp;and&nbsp;Oncology&nbsp;research’. By not excluding papers based on novelty, this journal facilitates the research and wishes to publish papers as long as they are technically correct and scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled, OPEN peer-reviewed, open-access INTERNATIONAL journal.</p> https://journalaorj.com/index.php/AORJ/article/view/72 Carpal Tunnel Syndrome Caused by Palmaris Profundus Sharing Common Sheath with Median Nerve 2023-03-14T13:00:00+00:00 Nouha Baba Senda Bellila bellilasenda@gmail.com Feten Sbei Mohamed Ali Sbai <p>Carpal tunnel syndrome is the most common entrapment neuropathy in adults, usually caused by thickening of the flexor retinaculum. Occasionally, compression of the median nerve at the wrist may be caused by the presence of an intracanalar tumor or anatomic variations. We report in this manuscript, the case of a carpal tunnel syndrome secondary to the presence of a palmaris profundus tendon included in a common sheath with the median nerve.</p> 2023-03-14T00:00:00+00:00 Copyright (c) 2023 Baba et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. https://journalaorj.com/index.php/AORJ/article/view/71 Immunoexpression of Mutated BRAF V600E Protein in Papillary Thyroid Carcinoma 2023-01-14T12:29:13+00:00 Ohnmar Than ohnmarthan2@gmail.com Mie Mie Than Le՝Shwe Zin Nyo Me May Thyn <p><strong>Background and Objectives: </strong>In papillary thyroid cancer (PTC), BRAF V600E is the most prevalent genetic alteration, and in different populations, its frequency ranges from 29% to 83%. BRAF mutation is mostly detected by DNA-based molecular methods, which are labor-intensive and time-consuming. A method, immunohistochemistry (IHC), was recently introduced to detect BRAF-mutated proteins. This method enables a monoclonal BRAF V600E mutation-specific antibody that can distinguish BRAF V600E from wild-type protein in conventionally processed, formalin-fixed, paraffin-embedded tissue and the mutant protein that was directly visualized in tumour cells in a tissue context. This study aimed to determine the BRAF V600E-mutated protein's immunoexpression in papillary thyroid carcinoma.</p> <p><strong>Methodology: </strong>The study was a laboratory-based cross-sectional descriptive study. A total of 44 histologically proven paraffin-embedded tissue blocks of PTC were collected. Anti-BRAF V600E rabbit monoclonal primary antibody was used for immunohistochemistry on tissue sections, and the staining intensity was scored from 0 to 3 (+): 0, no cytoplasmic staining in tumour cells; 1: faint cytoplasmic staining in over 10% of tumour cells; 2+, moderate cytoplasmic staining in over 10% of tumour cells; 3+, strong cytoplasmic staining in over 10% of tumour cells. Tumour cells with a score of 1+, 2+, or 3+ were considered positive for mutated BRAF V600E immunoexpression, and those with a score of 0 were considered negative.</p> <p><strong>Results: </strong>Among 44 cases, 34 (77.3%) were positive, and 10 (22.7%) were negative for the mutated BRAF V600E protein by IHC staining. In terms of staining intensity, 4 (9.1%), 20 (45.5%), and 10 (22.7%) cases had IHC scores of 1+, 2+, and 3+, respectively. This study reported a high-frequency rate (77.3%) of mutated BRAF protein, similar to the frequency reported in other Asian countries. There was no association between mutated BRAF V600E protein status and either age or gender.</p> <p><strong>Conclusion:</strong> The most effective PTC diagnostic marker is BRAF V600E mutation. The IHC technique using BRAF V600E mutation-specific antibodies is relatively simple and faster and is therefore proposed as the most reliable first-line method for detecting BRAF V600E-mutated proteins.</p> 2023-01-02T00:00:00+00:00 Copyright (c) 2023 Than et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.